Bioequivalency Study of Morphine Sulfate Injection, Solution and Tablet Under Fasted Conditions
Not Applicable
Completed
- Conditions
- Pain
- Registration Number
- NCT00994942
- Lead Sponsor
- Roxane Laboratories
- Brief Summary
Determine the pharmacokinetics and optimize study design for subsequent studies with morphine sulfate tablets and solution.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to morphine sulfate or any comparable or similar product.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method bioequivalence determined by statistical comparison Cmax 7 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CEDRA Clinical Research
🇺🇸Austin, Texas, United States